United States: Genentech And Partners Voluntarily Dismiss IPR Appeals Related To Genentech's ACTEMRA® (Tocilizumab) - Goodwin Procter LLP
Tuesday, 5 March 2024
On February 12, 2024, Chugai, Genentech, and Hoffmann-La Roche filed a motion for voluntary dismissal of their appeals of the PTAB's Final Written Decisions in IPR2022-00578 and IPR2022-00579.
|
||||
You Might Like |
||||
